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Abstract 
The κ-opioid receptor (KOR) and bradykinin B2 receptor (B2R) are involved in a variety of 
important physiological processes and share many similar characteristics in terms of their 
distribution and functions in the nervous system. We ﬁrst demonstrated the endogenous 
expression of KOR and B2R in human SH-SY5Y cells and their co-localization on the 
membrane of human embryonic kidney 293 (HEK293) cells. Bioluminescence and 
ﬂuorescence resonance energy transfer and the proximity ligation assay were exploited to 
demonstrate the formation of functional KOR and B2R heteromers in transfected cells. 
KOR/B2R heteromers triggered dynorphin A (1–13)-induced Gαs/protein kinase A signaling 
pathway activity, including upregulation of intracellular cAMP levels and cAMP-response 
element luciferase reporter activity, resulting in increased cAMP-response element-binding 
protein (CREB) phosphorylation, which could be dampened by the protein kinase A (PKA) 
inhibitor H89. This indicated that the co-existence of KOR and B2R is critical for CREB 
phosphorylation. In addition, dynorphin A (1–13) induced a signiﬁcantly higher rate of 
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proliferation in HEK293-KOR/B2R and human SH-SY5Y cells than in the control group. 
These results indicate that KOR can form a heterodimer with B2R and this leads to increased 
protein kinase A activity by the CREB signaling pathway, leading to a signiﬁcant increase in 
cell proliferation. The nature of this signaling pathway has signiﬁcant implications for the role 
of dynorphin in the regulation of neuroprotective effects. 
 
Keywords 
G-protein-coupled receptor (GPCR); κ-Opioid receptor (KOR); Bradykinin B2 receptor 
(B2R); Resonance energy transfer (RET); cAMP-response element-binding protein 
(CREB); Heterodimerization 
 
 
1. Introduction 
 
G-protein-coupled receptors (GPCRs), which consist of seven membrane-spanning 
α-helical structures, are the largest family of cell surface receptors capable of binding to a 
wide array of molecules (i.e., ions, nucleotides, amino acids, photons, amines, and peptides) 
[1]. Once activated, a GPCR changes its conformation to activate speciﬁc heterotrimeric G 
proteins, followed by transduction of stimulatory or inhibitory signals from the extracellular 
milieu to intracellular signaling molecules [2-4]. Because they are involved in the regulation 
of nearly every physiological process, GPCRs have been considered as important targets for 
human therapeutics [5, 6]. Although GPCRs were initially thought to be, and function 
exclusively as, monomeric entities [7, 8], increasing evidence indicates that they can form 
homomeric or heteromeric GPCR complexes in intact cells[9-13].  
Endogenous opioid peptides include three major types of neuropeptides (enkephalins, 
endorphins, and dynorphins (DYNs)), which exert their actions through three types of opioid 
receptors: the μ-opioid (MOR), δ-opioid (DOR), and κ-opioid (KOR) receptors. All three 
opioid receptors belong to the large family of GPCRs and are distributed in the central 
nervous system (CNS) and peripheral nervous system [14]. Among the opioid receptors, the 
KOR, which is specifically activated by the endogenous opioids DYNs [15], plays an 
important role in a variety of physiological processes including analgesia, anti-pruritic activity 
[16], fluid homeostasis, dieresis [14, 17], cardiovascular regulation [18], and modulation of 
the hypothalamic-pituitary axis [19]. KOR signals mainly through activation of the Gαi 
subunit to inhibit cAMP production [20]. The DYN/KOR system has neuroprotective effects 
in vivo and in vitro, such as improving the survival of cats with cerebral ischemia [21, 22] or 
ameliorating L-DOPA-induced dyskinesia symptoms in a rat model of Parkinson’s disease 
[23]. 
The bradykinin B2 receptor (B2R) and bradykinin B1 receptor (B1R), which are both 
GPCRs, play prominent roles in a wide variety of physiological and pathological responses 
after being activated by bradykinin (BK) and des-Arg9-BK, respectively [24-26]. Typically, 
B2R is constitutively expressed in a variety of cell types, while B1R expression is induced by 
injury or inﬂammation [26]. Most of the physiological functions of kinins are mediated by 
B2R, which is present in most tissues including the CNS [27]. B2R participates in many 
signaling cascades, but generally couples with the Gαq protein, which activates phospholipase 
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C (PLC), leading to a transient increase in intracellular Ca
2+
 [28]. Increasing data indicate that 
the Gαs-cAMP-PKA signaling pathway also functions downstream of B2R, leading to various 
biological effects [26, 29]. Like KORs, numerous studies have revealed that B2R exerts 
neuroprotective effects in the CNS, such as increasing memory preservation in Alzheimer's 
disease and promoting survival through suppressing apoptosis and inflammation in ischemic 
stroke [30-32].  
Numerous GPCRs dimerize, and KORs and B2Rs are no exception [33-35]. KOR and B2R 
share many congenerous characteristics. They share similar distributions in the CNS and 
cardiovascular system and exhibit similar functions in cardiovascular protection and 
neuroprotection. In addition, both receptors mediate neuroprotection through the PI3K/Akt 
signaling pathway [36, 37]. Interestingly, human neuroblastoma cells (SH-SY5Y cells) 
co-express KOR and B2R [38, 39], and these receptors have been implicated in the regulation 
of neurogenesis and neuroprotection [40]. Despite these similarities in distribution and 
functions, possible direct physical and functional interactions between KOR and B2R have 
not been examined. 
In the present study, we aimed to investigate whether KOR and B2R can form heterodimers 
using bioluminescence resonance energy transfer (BRET), ﬂuorescence resonance energy 
transfer (FRET), and the proximity ligation assay (PLA) in transfected human embryonic 
kidney 293 (HEK293) cells. Meanwhile, we examined whether signal transduction of the 
heterodimer was altered by dynorphin A (1–13) (Dyn A(1–13)) or BK, with particular focus 
on the effects of the heterodimers on the transcription factor cAMP-response element-binding 
protein (CREB), which plays a critical role in the modulation of neuroprotection [41-43]. This 
work further reveals the molecular mechanism underlying neuroprotection mediated by 
heterodimers in the CNS and provides an experimental basis for exploring new breakthroughs 
in brain injury and neurodegeneration. 
 
2. Materials and methods 
 
2.1. Peptides, reagents, and antibodies 
Human Dyn A(1–13) and BK were obtained from Phoenix Pharmaceuticals (Belmont, 
USA). The mammalian expression vector pcDNA3.1(+) and Lipofectamine™ 2000 were 
obtained from Invitrogen (Paisley, UK). Forskolin (FSK), 3-isobutyl-1-methylxanthine 
(IBMX), the Duolink PLA and protein kinase C (PKC) inhibitor Bisindolylmaleimide II 
(BisII) were all purchased from Sigma-Aldrich Shanghai Trading Co Ltd (Shanghai, China). 
PKA inhibitor H89 was purchased from Beyotime (Shanghai,China). Anti-KOR and anti-B2R 
antibodies were purchased from Novus (Littleton, USA). Anti-phospho-CREB and anti-total 
CREB antibodies were purchased from Cell Signaling Technology (Danvers, MA, USA).  
  
2.2. Plasmid constructs 
The pcDNA3.1-KOR and pcDNA3.1-B2R plasmids were obtained from the UMR cDNA 
Resource Center (University of Missouri-Rolla, USA). Cyan ﬂuorescent protein (CFP) or 
mVenus was attached to the C-terminus of KOR, B2R, and mouse orexin type 2α receptor 
(mOX2αR) by inserting the open reading frame of KOR, B2R, or mOX2αR into the CFP-N1 
or mVenus-N1 vector to create KOR-CFP, B2R-Venus, or mOX2αR-Venus. For the 
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KOR-Rluc plasmid, the coding sequence of human KOR lacking a stop codon was subcloned 
into pRluc-N1 (BioSignal Packard, Inc., Montreal, Canada). To construct pEGFP-B2R, cDNA 
encoding human B2R was cloned into pEGFP-C1 (Clontech, USA). The plasmids pCRE-Luc 
(which was used to detect the cAMP-response element (CRE)) and pSRE-Luc (which were 
used to detect the serum response element (SRE)) were purchased from Stratagene (La Jolla, 
CA, USA). The plasmid pRL-TK was purchased from Promega (Madison, WI, USA). To 
construct the Gαi2-Rluc8, Gαq-Rluc8, and Gαs-Rluc8 fusion proteins, Rluc8 (humanized 
regular Renilla Luciferase 8) was PCR-ampliﬁed and inserted at position 91 of Gαi2, 97 of 
Gαq, and 113 of Gαs, respectively [44]. All the resulting constructs were conﬁrmed by 
commercial sequencing. 
 
2.3. Cell culture and transfection 
HEK293, SH-SY5Y, and CHO cells obtained from the American Tissue Culture Collection 
were cultured in Complete Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen) 
containing 10% fetal calf serum, 100 U/ml penicillin, and 100 μg/ml streptomycin at 37°C in 
a 5% CO2 incubator. To establish stable cell lines, HEK293 cells were transfected with the 
plasmids pcDNA3.1-KOR, pcDNA3.1-B2R, and pcDNA3.1-KOR/pcDNA3.1-B2R, 
respectively. Cells were selected with G418 (Gibco, Invitrogen) for 8 weeks. Receptor 
expression in the stable cell lines was assessed by reverse transcription-polymerase chain 
reaction (RT-PCR). 
 
2.4. RT-PCR 
To detect the endogenous expression of KOR and B2R, total RNA was extracted and 
puriﬁed from human SH-SY5Y cells for RT-PCR. The primers were as follows: KOR, 
forward 5′-CTGGTGGGACCTCTTC-3′ and reverse 5′-ATGGGATTCAGGCTACT-3′ 
(product length: 320 bp); and B2R, forward 5′-GCTGCGGAACAACGAG-3′ and reverse 
5′-TGGTACACCTCCCAAGAC-3′ (product length: 300 bp). Ten microliters of the reaction 
mixtures were subsequently electrophoresed on a 1.5% agarose gel and visualized by 
ethidium bromide staining. 
 
2.5. Immunostaining and confocal microscopy 
HEK293 cells grown on coverslips were transiently transfected with pEGFP-B2R and 
pcDNA3.1-KOR and ﬁxed after 24 h as previously described [33]. Non-speciﬁc binding was 
blocked by incubation with 3% bovine serum albumin prepared in phosphate-buffered saline 
(PBS) containing 0.01% Triton X-100 for 1 h at room temperature. Cells were washed three 
times with PBS and then incubated overnight with an anti-KOR monoclonal antibody (1:200) 
in PBS at 4°C. Cells were washed three times with PBS, followed by incubation with 
Alexa-Fluor
®
647 (red)-conjugated secondary antibodies (1:400) (Molecular Probes, 
Invitrogen) for 1 h at room temperature. After a ﬁnal wash with PBS, cells were examined 
using a Leica DMRE laser scanning confocal microscope (Leica, Milton Keynes, UK). 
 
2.6. BRET measurements 
HEK293 cells were transiently co-transfected with vectors encoding Rluc fusion or Venus 
fusion proteins. Twenty-four hours after transfection, cells were washed twice, detached, and 
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transferred (10
5 
cells/well) to a 96-well microplate (Corning 3600, white opaque plates) for 24 
h in HEPES-buffered phenol red-free medium (Invitrogen, Life Technologies). Cells were 
then washed twice and resuspended in D-PBS (PBS containing 0.5 mM MgCl2 and 0.1% (w/v) 
glucose). Coelenterazine H substrate was added to a final concentration of 5 μM. When 
appropriate, cells were pretreated with Dyn A(1–13) or BK at a final concentration of 100 nM 
for 10 min prior to addition of the substrate. Analysis was carried out immediately at 37°C 
using a Tristar LB941 plate reader (Berthold Technologies, Bad Wildbad, Germany). The 
BRET ratio was calculated by subtracting the ratio of the emission at 535 ± 30 nm to the 
emission at 485 ± 20 nm in cells expressing the Rluc fusion protein alone from the same ratio 
in cells co-expressing the Rluc and Venus fusion proteins. The results are expressed as the 
“BRET ratio” or alternatively as “mBRET” (mBRET = 1000 × BRET ratio). As a negative 
control, cells co-transfected with KOR-Rluc and mOX2αR-Venus were used. 
BRET saturation curves were obtained by transfecting increasing amounts of plasmid 
encoding the Venus-tagged construct against a constant amount of the Rluc-tagged donor 
constructs. The total amount of plasmid DNA was kept constant by adding empty plasmid. 
Data were expressed as the mBRET, which was calculated as described above. 
 
2.7. FRET experiments 
To further explore the heterodimerization of KOR and B2R, FRET was performed in living 
cells. The donor plasmid KOR-CFP and the receptor plasmid B2R-Venus were co-transfected 
into HEK293 cells. As a negative control, KOR-CFP and mOX2αR-Venus were 
co-transfected into HEK293 cells. FRET signals were detected using an OLYMPUS I ×71 
ﬂuorescence inverted microscope and MetaFluor 7.0 software, which allowed the sequential 
integration of light signals detected with two ﬁlter settings (CFP: excitation at 436 ± 10 nm 
and emission at 480 ± 20 nm; mVenus: excitation at 480 ± 20 nm and emission at 535 ± 15 
nm; FRET: excitation at 436 ± 10 nm and emission at 535 ± 15 nm). Corrected FRET was 
calculated using the equation: FRETc = FRET − (coefﬁcient B × CFP) − (coefﬁcient A × 
Venus), where CFP, Venus, and FRET values correspond to background-corrected images 
obtained through the CFP, Venus, and FRET channels. Coefﬁcient B and coefﬁcient A 
correspond to the values obtained for the CFP (donor) and Venus (acceptor) bleed-through 
co-efficients, respectively, which were calculated using cells transfected with CFP and 
mVenus individually [45, 46]. To correct the FRET levels for the various amounts of donor 
(eCFP) and acceptor (eYFP), normalized FRET was calculated using the following equation: 
FRETN = FRETc / (CFP × Venus), where FRETc, CFP, and Venus are equal to the 
ﬂuorescence values obtained from single-transfected cells. 
 
2.8. PLA 
HEK293-KOR/B2R cells were grown and ﬁxed with 4% paraformaldehyde prepared in 
PBS on 6-well tissue culture slides. To visualize receptor interactions, slides were blocked 
with Blocking Solution and incubated with rabbit anti-B2R and goat anti-KOR antibodies at 
4°C overnight in a humidifying chamber. Slides were then washed and incubated with 
secondary anti-rabbit/goat antibodies conjugated with plus and minus Duolink II PLA probes 
(1:5) at 37°C for 1 h. Slides were washed again and then incubated with ligation-ligase 
solution (30 min at 37°C), followed by incubation with amplification-polymerase solution (3 
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h at 37°C). Slides were then mounted with a minimal volume of Duolink II mounting medium 
containing 4′,6-diamidino-2-phenylindole (DAPI) for 30 min. PLA signals [Duolink In Situ 
Detection Reagents Red (λ excitation/emission, 598/634 nm)] were identified as fluorescent 
spots under a fluorescence microscope (Leika TCS SP5) at room temperature. 
 
2.9. BRET assay for cAMP  
Intracellular cAMP was assayed using an Epac cAMP BRET biosensor [47]. Briefly, 
YFP-Epac-RLuc plasmids and receptors of interest were co-transfected into HEK293 cells. 
After 24 h, cells were collected, distributed in a 96-well white opaque microplate, and 
cultured for another 24 h in HEPES-buffered phenol red-free medium. Cells were then 
washed once with PBS and resuspended in D-PBS. BRET between RLuc and YFP was 
measured at 20°C in the presence of Coelenterazine H (5 μM) and the nonspecific 
phosphodiesterase inhibitor IBMX (40 μM). Cells were stimulated with agonists in the 
absence of FSK (10 μM) 5 min later. After incubation for 5 min, BRET readings were 
collected using a Tristar LB941 plate reader. The BRET signal was determined by calculating 
the ratio of emission of YFP (520–570 nm) to RLuc (370–480 nm). 
 
2.10. Luciferase gene reporter assays 
To conduct SRE and CRE luciferase assay, cells stably expressing KOR, B2R, or 
KOR/B2R were co-transfected with the pSRE-Luc (SRE tagged with luciferase) or 
pCRE-Luc (CRE tagged with luciferase) plasmid, which contain ﬁreﬂy luciferase, along with 
pRL-TK (Promega) expressing Renilla luciferase. About 24 h after transfection, cells were 
treated with Dyn A(1–13) (100 nM ﬁnal concentration) as indicated for 6 h in serum-free 
DMEM at 37°C, washed with PBS, and lysed with the reagent containing the luciferase 
substrate. For SRE luciferase assay, cells were pretreated with 1 μM PKC inhibitor BisII for 2 
h prior to ligand stimulation. As a control, the basal cells were also treated with BisII. The 
activities of ﬁreﬂy luciferase and Renilla luciferase were measured by the Dual-Luciferase 
Reporter Assay System using the Tristar LB941 instrument. The results were expressed as 
mean ± SEM of six independent experiments performed in duplicate. The ratio of the ﬁreﬂy 
luciferase luminescence signal to that of Renilla luciferase was determined. 
 
2.11. Western blotting 
HEK293 and SH-SY5Y cells were lysed and the proteins concentration was quantified with 
a BCA Analysis Kit (KeyGEN, Nanjing, China). Proteins were separated on 10% SDS-PAGE 
gels and subsequently transferred to PVDF membranes. The membranes were blocked with 
5% nonfat milk at room temperature for 1 h and then incubated with a primary antibody 
(1:1000) against KOR, B2R, or GAPDH in TBST at 4°C overnight. After washing three times 
with TBST for 10 min, the membrane was incubated with a HRP-conjugated secondary 
antibody (1:5000) at room temperature for 1 h and washed three times for 10 min with TBST. 
The immunoreactive proteins were visualized by ECL chemiluminescent reagent (Pierce 
Biotechnology). An anti-GAPDH antibody was used as a loading control. 
To assay CREB activation, HEK293 cells expressing KOR, B2R, or KOR/B2R cells were 
pre-treated with or without protein kinase A (PKA) inhibitor H89 (10 µM, 30 min) or 
phospholipase C (PLC) inhibitor U73122 (10 µM, 30 min), followed by stimulation with Dyn 
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A(1–13) (100 nM) for 5 min, respectively. Following treatment, cells were washed, harvested, 
and lysed in RIPA lysis buffer. Thereafter, 10 μg of cell extracts was separated by 10% 
SDS-PAGE. Gel transfer was performed at 150 mA for ~90 min. Phosphorylation of CREB 
was detected by immunoblotting with an antibody against phospho-CREB (1:1000). As a 
loading control, the same membranes were re-probed with an anti-total CREB antibody 
(1:1000). The band intensities were measured by densitometric analysis, and the change in 
CREB phosphorylation was calculated as the phospho-CREB/CREB ratio. 
 
2.12. Cell proliferation assays 
HEK293-KOR/B2R and human SH-SY5Y cells were seeded into a 96-well plate at a 
density of 10
4
 cells per well. After 24 h, the cells were treated with 1, 10, and 100 nM Dyn 
A(1–13) for another 24 h. Cell proliferation was measured using a CCK-8 (Dojindo, Japan) 
viability assay. HEK293, HEK293-KOR, HEK293-B2R, and HEK293-KOR/B2R cells were 
seeded in a 96-well plate at a density of 10
4
 cells per well in quadruplicate. After 24 h, all 
cells were stimulated with 100 nM Dyn A(1–13) for 24 h. The CCK-8 assay was performed 
according to the manufacturer's instructions. Following incubation, the absorbance of the 
suspension was measured at 450 nm. Each sample was run in quadruplicate. Wells containing 
media alone were included as a control. 
 
2.13. Statistical analysis 
All the data are shown as the means ± SEM. The data were presented and analyzed using 
GraphPad Prism v6.0. Sigmoidal curves were fitted to the dose-response data using non-linear 
regression. A one-way ANOVA was used for multiple group comparisons, followed by 
Tukey's test. All experiments were repeated at least three times, and representative 
experiments are shown in the ﬁgures. 
 
3. Results 
 
3.1. Endogenous expression of KOR and B2R in SH-SY5Y cells 
Bands of 320 and 300 bp were ampliﬁed using RT-PCR, suggesting that SH-SY5Y cells 
expressed KOR and B2R (Fig. 1A and B). SH-SY5Y cells also expressed KOR (43 kDa) and 
B2R (45 kDa) proteins (Fig. 1C and D). However, neither of the receptors was detected in 
HEK293 cells. 
 
3.2. Co-localization of KOR and B2R in HEK293-KOR/B2R cells 
To identify the co-localization of KOR and B2R in HEK293 cells co-transfected with 
pcDNA3.1-KOR and N-terminal EGFP-tagged B2R, immunoﬂuorescence image analysis was 
carried out using confocal microscopy. KOR and B2R were predominantly expressed at the 
cell membrane (Fig. 1E), implying that they may interact. Nuclei were visualized by DAPI 
staining. 
 
3.3. Heterodimerization of KOR and B2R determined by BRET and FRET analyses  
To determine whether KOR and B2R can form a heterodimer, BRET analysis was 
performed in HEK293 cells co-transfected with the plasmids KOR-Rluc and B2R-Venus. The 
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BRET ratio was signiﬁcantly higher in cells co-expressing KOR-Rluc and B2R-Venus than in 
cells transfected with KOR-Rluc alone or co-transfected with Rluc and B2R-Venus, Venus 
and KOR-Rluc, or KOR-Rluc and mOX2αR-Venus (Fig. 2A). These results indicated the 
constitutive association of KOR and B2R. To evaluate whether KOR/B2R heteromerization is 
influenced by agonists of the two receptors, BRET analyses were performed in the presence 
of Dyn A(1–13) or/and BK. Neither agonist affected BRET signals (data not shown). 
To investigate whether the interaction of KOR and B2R is speciﬁc, BRET saturation assays 
were performed. BRET signals representing the transfer of energy between KOR-Rluc and 
B2R-Venus increased as a hyperbolic function of the concentration of the Venus fusion 
construct added until a plateau was reached, whereas Rluc and B2R-Venus as well as Venus 
and KOR-Rluc exhibited a nonspeciﬁc linear relationship (Fig. 2B). These results indicated 
that the interaction between KOR and B2R is speciﬁc and is not due to receptor 
overexpression and random collisions. 
For competitive BRET analysis, fixed amounts of KOR-Rluc/B2R-Venus and increasing 
amounts of unlabeled KOR or B2R were co-expressed in HEK293 cells. BRET signals 
decreased as the concentration of unlabeled KOR or B2R increased (Fig. 2C and D). These 
data further confirmed the specific formation of KOR and B2R heterodimers. 
FRET was performed to further explore the interaction between KOR and B2R. HEK293 
cells were transfected with KOR-CFP (a), B2R-Venus (b), KOR-CFP and mOX2αR-Venus (c), 
or KOR-CFP and B2R-Venus (d) (Fig. 3A). In images of FRET, the site of interaction will be 
marked as yellow or red. Moreover, a more intense color means a stronger interaction. There 
was no signiﬁcant FRET in all single-transfected cells (Fig. 3A and B). As a negative control, 
no signiﬁcant FRET was visualized in cells co-transfected with KOR-CFP and 
mOX2αR-Venus. However, a notable FRET signal was clearly detected in HEK293 cells 
co-transfected with KOR-CFP and B2R-Venus. FRET signals could also be detected in CHO 
cells co-transfected with KOR-CFP and B2R-Venus (Fig. 3C), suggesting that FRET occurred 
in distinct cell lines. 
 
3.4. Heterodimerization of KOR and B2R determined by the PLA 
To further confirm the formation of KOR-B2R heteromeric complexes, the PLA was 
performed to specifically detect the close proximity of these two receptors in HEK293 cells 
stably expressing both receptors (Fig. 4A). There were strong PLA signals in 
HEK293-KOR/B2R cells, but no signals in the control group incubated with only one 
secondary antibody (Fig. 4B). These results from stable cells suggest that KOR and B2R can 
interact and that the observed proximity between the receptors corresponds to direct 
receptor–receptor interactions. 
 
3.5. Heterodimerization of KOR and B2R increases the intracellular cAMP concentration 
upon Dyn A(1–13) stimulation 
We used the cAMP BRET biosensor to determine whether the heterodimer affects cAMP 
accumulation. The sensor consists of an N-terminal truncated variant of EPAC tagged with 
Rluc and YFP at the N and C termini, respectively (Fig. 5A). Upon binding of cAMP, the 
signal of the biosensor decreases due to a conformational change that presumably increases 
the distance between the donor and acceptor. The reduction of the BRET signal with FSK is 
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consistent with its role as a stimulator that promotes cAMP production (Fig. 5B). After 
treatment with Dyn A(1–13), BRET signals were signiﬁcantly lower in HEK293-KOR/B2R 
cells than in HEK293-KOR and HEK293-B2R cells (Fig. 5C). However, when treated with 
BK, BRET signals in HEK293-KOR/B2R cells did not differ from those in HEK293-B2R 
cells (Fig. 5D), suggesting that BK cannot enhance the cAMP level through the KOR/B2R 
heterodimer. 
 
3.6. Detection of interactions between Gα subunits and KOR/B2R heterodimers using BRET  
To investigate potential receptor-G protein interactions, BRET assays were performed in 
living HEK293 cells co-expressing Gαs-Rluc8, Gαi2-Rluc8, or Gαq-Rluc8 and either 
KOR-Venus, B2R-Venus, or B2R, in combination with the complementary untagged G 
protein subunits Gβ1/Gγ2. The BRET ratio between Venus-tagged KOR and Rluc8-tagged 
Gαs signiﬁcantly increased after Dyn A(1–13) stimulation compared with that in cells 
expressing KOR or B2R alone (Fig. 6A), suggesting that heterodimerization of KOR and B2R 
leads to Gαs protein binding and activation upon agonist stimulation. However, when KOR 
and B2R were co-expressed, the changes of the BRET ratio between Venus-tagged KOR and 
Rluc8-tagged Gαi2 after agonist stimulation were smaller than in cells expressing KOR alone 
(Fig. 6B). No BRET signal changes were detected between Gαq and receptors in any of the 
three cell types (Fig. 6C). Moreover, basal BRET signals were also observed in all cases, 
reﬂecting constitutive interactions between the receptor and G proteins. 
 
3.7. Dyn A(1–13) increases CRE-luc activity in HEK293-KOR/B2R cells 
To determine the effect of KOR and B2R heterodimers on downstream signaling, we 
detected the activity of CRE and SRE in HEK293-KOR, HEK293-B2R, and 
HEK293-KOR/B2R cells. CRE-luc activity was signiﬁcantly higher in HEK293-KOR/B2R 
cells than in HEK293-KOR and HEK293-B2R cells (P<0.01, Fig. 7A), whereas SRE-luc 
activity was decreased compared to that in HEK293-KOR cells (P<0.01, Fig. 7B). Further- 
more, the SRE-luc activity was completely blocked by PKC inhibitor BisII in HEK293-KOR 
cells and the same treatment has no effects on SRE-luc activities in other groups (Fig. 7B), 
suggesting that Dyn A(1-13) induced enhanced SRE activation depends upon PKC activity in 
HEK293-KOR cells. All the results showed that heterodimerization of KOR and B2R 
increased CRE activity depending on PKA activities when Dyn A(1–13) was added to 
HEK293-KOR/B2R cells, which further confirmed that the KOR/B2R heterodimer leads to an 
increase in Gαs binding. 
 
3.8. Dyn A(1–13) increases CREB phosphorylation in HEK293-KOR/B2R cells 
GPCR coupling to the stimulatory G protein (Gαs) stimulates adenylyl cyclase (AC) to 
increase CREB phosphorylation, while coupling to the inhibitory G protein (Gαi) inhibits AC 
and decreases CREB activation. To determine whether KOR/B2R heterodimers affect CREB 
phosphorylation, the time- and dose-dependent effects of Dyn A(1–13) on CREB activation 
were investigated. The ability of KOR and/or B2R to stimulate phosphorylation of CREB was 
assessed by treating cells with Dyn A(1–13) (10-7 M) for 0–60 min. Activation of either 
receptor did not affect the total CREB protein expression, and treatment with Dyn A(1–13) 
inhibited the activation of CREB in HEK293-KOR cells, with maximal inhibition at 5 min 
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and a return to near basal conditions after 60 min. However, a robust increase (maximal at 5 
min) in CREB phosphorylation was observed in HEK293-KOR/B2R cells, with a subsequent 
decline (Fig. 8A and C). In dose-dependent experiments, CREB activation decreased when 
concentrations of Dyn A(1–13) increased in HEK293-KOR cells. By contrast, CREB 
activation increased with increasing concentrations of Dyn A(1–13) in HEK293-KOR/B2R 
cells (Fig. 8B and D). B2R expression alone led to very little activation of CREB, whereas 
co-expression of KOR and B2R led to signiﬁcantly higher CREB phosphorylation than that in 
HEK293-B2R cells (Fig. 8B and D). Similarly, a dose-dependent effect on CREB activation 
was also observed in human SH-SY5Y cells (Fig. 8E), suggesting that Dyn A(1–13) can 
induce CREB phosphorylation. 
 
3.9. CREB phosphorylation mediated by KOR/B2R heterodimers is PKA-dependent and 
PLC-independent 
To examine whether CREB phosphorylation is PKA-dependent in HEK293-KOR/B2R 
cells, the cells were treated with the PKA inhibitor H89 prior to Dyn A(1–13). The level of 
CREB phosphorylation in HEK293-KOR/B2R cells was significantly lower with H89 
treatment than without H89 treatment (Fig. 9A and B). To determine whether the 
Gq/PLC/PKC pathway mediates CREB activation, a PLC-selective inhibitor, U73122, was 
applied. Pretreatment with 10 μΜ U73122 for 30 min did not signiﬁcantly change the level of 
CREB phosphorylation in HEK293-KOR/B2R cells (Fig. 9C and D). As a positive control, 
however, U73122 remarkably reduce the level of CREB phosphorylation in HEK293-OX1R 
cells (P<0.01) (Fig. S1). These results further indicate that the KOR/B2R heterodimer signals 
through the Gαs/cAMP/PKA/CREB pathway after stimulation by Dyn A(1–13) in 
HEK293-KOR/B2R cells.  
 
3.10. Dyn A(1–13) enhances proliferation of HEK293-KOR/B2R and SH-SY5Y cells 
The above results indicate that KOR and B2R form a heterodimer, thereby synergistically 
increasing cell signal transduction. To further investigate the role of the dimer in cell function, 
we performed a cell viability assay. Dyn A(1–13) had a significant effect on the proliferation 
of HEK293-KOR/B2R cells, and this functional outcome of KOR/B2R co-expression 
followed a dose-dependent pattern, reaching signiﬁcance at 10 nM (P<0.01) (Fig. 10A). 
Treatment with 10
-7 
M Dyn A(1–13) for 24 h signiﬁcantly increased the proliferation of 
HEK293-KOR/B2R cells, while the proliferation of HEK293-KOR and HEK293-B2R cells 
was not affected (Fig. 10B). In HEK293 cells, there were no signiﬁcant proliferative 
responses to Dyn A(1–13). Thus, KOR and B2R heteromerization is important for cell 
proliferation. Corresponding to its effects on CREB phosphorylation, Dyn A(1–13) promoted 
the proliferation of human SH-SY5Y cells (Fig. 10C). 
 
4. Discussion 
 
The ability of GPCRs to interact with each other as dimers or higher-order oligomers has 
received much attention. These complexes induce diverse signaling pathways, leading to 
effects on nearly every aspect of GPCR functions. For example, receptor heteromerization 
alters the cell surface delivery and retention of certain GPCRs [48], modulates G 
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protein-coupling [49], and causes cross-activation or cross-inhibition of signaling. KOR and 
B2R are becoming an increasingly important subject for investigation in a variety of 
neurological processes such as neuroprotection [37, 50]. 
In the present study, we confirmed the co-expression of KOR and B2R in SH-SY5Y cells 
by RT-PCR and Western blotting. Furthermore, immunoﬂuorescence staining showed the 
co-localization of KOR and B2R on the surface of HEK293 cells. We further identiﬁed the 
heterodimerization of KOR and B2R in co-transfected HEK293 cells using both BRET and 
FRET technology. The results showed that KOR constitutively heteromerizes with B2R, but 
not with the unrelated receptor mOX2αR (Fig. 2 and Fig. 3). BRET saturation and 
competitive analyses confirmed that the interaction was speciﬁc. A series of studies suggest 
that ligands may modulate the extent of dimerization [10, 33, 51], whereas Dyn A(1–13) or 
BK treatment had no effect on the interaction between KOR and B2R. 
The PLA was performed to further confirm the interaction between KOR and B2R. This 
assay is a powerful tool for studying protein-protein interactions in vitro and in vivo [52, 53]. 
The current study demonstrates that KOR can form heterodimers with B2R in stably 
transfected cells (Fig. 4). Because the PLA assay is conducted on fixed tissue, transient 
interactions can be easily detected, in contrast with BRET and FRET assays. Furthermore, 
signal ampliﬁcation by rolling-circle ampliﬁcation increases the number of ﬂuorophores, 
meaning the PLA has high sensitivity with less background and the unique ability to quantify 
dimerization signals. 
Taken together, we provide sufficient evidence of KOR-B2R heterodimers. In general, 
GPCR heterodimerization may inﬂuence signaling pathways, and heteromer-specific 
signaling is a marker of heteromer formation [12, 13, 54, 55]. For example, heteromers of the 
CB1 and D2 receptors can induce an apparent shift in CB1 signaling from Gαi to Gαs [56]. 
Lee et al. demonstrated that D1-D2 heteromers switch D1 from Gαs to Gαq signaling [57]. 
Generally, the mGlu2 and 5-HT2A receptors couple with Gi and Gq proteins, respectively. 
Several studies report that hallucinogenic 5-HT2A receptor agonists activate both Gq and Gi 
proteins when the 5-HT2A receptor forms heteromers with the mGlu2 receptor [58, 59]. Our 
previous study also found that orexin receptor 1 and KOR can form a heterodimer, which 
couples with Gαs, leading to increased PKA activity and upregulation of intracellular cAMP 
levels [60]. KORs are coupled with heterotrimeric Gi/o proteins [61], inhibiting AC and 
cAMP levels and decreasing calcium levels via the Gβγ subunit. By contrast, B2R is generally 
reported to signal through the Gαq-PLC pathway, stimulating a transient increase in 
intracellular Ca
2+ 
[26]. Here, we explored whether KOR/B2R heterodimers affect signal 
transduction and levels of signaling molecules. Using an EPAC cAMP BRET biosensor, we 
studied ligand-induced changes of cAMP, a second messenger that directly affects the 
functions of many regulatory proteins. The cAMP BRET biosensor is a powerful tool to 
measure cAMP levels in real time. When the cAMP level increases, BRET ratios decrease due 
to a conformational change that leads to a larger distance between Rluc and YFP [47]. GPCRs 
that couple to Gαs or Gαi are thus suitable targets for investigations with this sensor. 
Moreover, the BRET signal with this sensor is reversible after the agonist is removed. cAMP 
accumulation was signiﬁcantly higher in co-transfected cells than in single-transfected cells. 
Interestingly, Dyn A(1–13), but not BK, activated cAMP signaling through KOR/B2R 
heteromers (Fig. 5), suggesting that heteromerization leads to different affinities for ligands, 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
Novel Signaling of Dynorphin at κ-Opioid Receptor/Bradykinin B2 Receptor Heterodimers 
12 
 
resulting in a novel signaling pathway. Similar results were reported in other studies. For 
example, treatment with isoproterenol increases the level of phosphorylated MAPK in cells 
co-expressing DOR and β2 adrenergic receptor (β2AR), whereas opioid-mediated 
phosphorylation of MAPK is not significantly altered, indicating that the DOR/β2AR 
heterodimer has different affinities for both ligands [62]. 
To further examine whether the KOR-B2R heterodimer is coupled to Gαs proteins to 
increase cAMP levels, the BRET assay was performed to detect the effects of the heteromer 
on G-protein coupling. Interestingly, although it is reported that KOR and B2R mainly couple 
with Gαi and Gαq, respectively [26, 61], signiﬁcant agonist-promoted BRET was observed 
between receptors and Gαs proteins in co-transfected HEK293 cells when stimulated with 
Dyn A(1–13). The results indicate that Gαs protein is activated by KOR/B2R heterodimers. 
By contrast, activation of Gαs was not detected in HEK293 cells expressing KOR or B2R 
alone, suggesting that KOR/B2R heterodimers enhance Gαs-protein coupling and lead to a 
novel signaling pathway. 
The Gα subunit dissociates from Gβγ dimers after the GPCR is activated and subsequently 
interacts with downstream effectors and initiates a cascade of downstream second messenger 
pathways, eventually inducing gene transcription by various response elements including 
CRE, SRE, NFAT-RE, and serum response factor response element (a mutant form of the 
SRE). To explore the inﬂuence of KOR/B2R heterodimers on the Gαs/Gαq/Gαi signaling 
pathways, we detected downstream signals of CRE and SRE in stably transfected cells using a 
dual reporter gene assay, which is a powerful tool to decipher downstream G-protein signaling 
[63]. SRE activity was lower in co-transfected cells than in HEK293-KOR cells, while there 
was no significant difference between HEK293-KOR/B2R cells and HEK293 cells (Fig. 7B). 
By contrast, CRE activity was signiﬁcantly higher in co-transfected cells than in 
single-transfected cells and HEK293 cells (Fig. 7A), which is consistent with the evaluation 
of cAMP accumulation, confirming that the major downstream signaling of KOR/B2R 
heteromers is the cAMP pathway via Gαs protein. Taken together, our data suggest that 
dimerization of KOR and B2R up-regulates the Gαs-mediated cAMP signaling pathway. 
Previous studies demonstrate that a GPCR heteromer can “choose” a completely new G 
protein. For example, the dopamine receptors D1R and D5R usually couple with Gαs/olf 
proteins, D2R and D4R couple with Gαi/o proteins, while the D1R-D2R and D5R-D2R 
heteromers both couple preferentially with Gαq proteins [64]. These results indicate that the 
ligand-binding site of receptors is altered by dimer formation and that the receptor 
heterodimer can form distinct conformations to couple with distinct G proteins, leading to a 
speciﬁc signaling pathway. Similarly, our findings also support the idea that allosteric 
interactions between KOR and B2R protomers can elicit changes of signaling cascades. 
In general, the main role of cAMP is to activate cAMP-dependent PKA, which 
phosphorylates cytoplasmic and nuclear proteins and activates the transcription of target 
genes [65]. As a nuclear transcriptional factor, CREB mediates cAMP-induced gene 
expression via binding to the CRE in gene promoter regions, which plays an important role in 
diverse biological processes such as development and differentiation of the nervous system 
[66], learning, memory, addiction, and modulation of cancer pain [67]. 
In the present study, Dyn A(1–13) led to a time-dependent and dose-dependent increase in 
phosphorylation of CREB in HEK293-KOR/B2R cells, whereas total CREB levels remained 
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unaltered (Fig. 8). However, the level of CREB phosphorylation was lower in HEK293 cells 
transfected with KOR or B2R alone than in co-transfected cells. The increased 
phosphorylation of CREB might be mediated by the increase in the intracellular cAMP 
concentration, which was consistent with our previous data (Fig. 5). Interestingly, Dyn 
A(1–13) also induced a dose-dependent increase in phosphorylation of CREB in human 
SH-SY5Y cells expressing both receptors (Fig. 8E). Furthermore, we tested CREB activation 
in HEK293-KOR/B2R cells in the presence of the PKA inhibitor H89 or the PLC inhibitor 
U73122. The results indicate that H89, but not U73122, blocked CREB activation in 
HEK293-KOR/B2R cells (Fig. 9), suggesting that CREB is phosphorylated via the 
Gαs/cAMP/PKA/CREB signaling pathway upon co-expression of the two receptors. Thus, the 
underlying mechanism may be conformational changes in the receptors affecting dimer-G 
protein binding, although, apart from heterodimers, monomers of KOR and B2R would still 
activate Gαi and Gαq, respectively.  
In addition to its roles in other physiological processes, increasing studies strongly support 
a role for CREB as a neuroprotectant. Mäkelä et al. reported that the peroxisome 
proliferator-activated receptor-γ agonist GW1929 influences CREB signaling in human 
dopaminergic neurons, contributing to increased cell viability [41]. Liu et al. demonstrated 
that activation of CREB pathways contributes to neurite extension of PC12 cells [42]. Several 
studies report that DYN/KOR and BK/B2R systems both participate in the process of 
neuroprotection [37, 68-70]. To further explore whether the heterodimer of KOR and B2R 
affects cell viability, cell proliferation was investigated. After treatment with Dyn A(1–13), 
the proliferation of HEK293-KOR/B2R cells was signiﬁcantly higher than that of 
HEK293-KOR and HEK293-B2R cells (Fig. 10). Furthermore, Dyn A(1–13) induced the 
proliferation of human SH-SY5Y cells in dose-dependent manner (Fig. 10C). These results 
indicate that Dyn A(1–13) plays a neuroprotective role via increasing the proliferation of 
SH-SY5Y cells.  
Dyn A(2–17), a des-tyrosyl fragment of DYN A, has a very low affinity for KOR. Liu et al. 
found that Dyn A(1–17) and Dyn A (2–17) protect neurons from damage with an equal 
potency [22], suggesting that the neuroprotective effect of DYN is not mediated through 
binding to the KOR, but rather through a novel mechanism. As we know, Dyn A mediated 
neuroinhibitory eﬀects through the opioid receptors. Interestingly, Lai et al. found that 
non-opioid fragment Dyn A(2-13) can promote hyperalgesia through agonist action at 
bradykinin receptors, especially B2R, in a neuropathic pain model [71]. Conversely, 
non-opioid [des-Arg
7
]-Dyn A(4-11) and its analogues, which also directly interact with BK 
receptors, can inhibit Dyn A-induced neuro-excitatory eﬀects and hypersensitivities[72, 73], 
but this ligand was quickly degraded. Compared with [des-Arg
7
]-Dyn A(4-11), its analogue 
[D-Leu
5
, des-Arg
7
]-DynA-(4−11) modified at Leu5 is very stable, and the ligand can also 
binds to the BK receptors with high aﬃnity and possesses the same potent antihyperalgesic 
eﬀects[74]. These studies suggested that modified Dyn A has a promising treatment for 
chronic neuropathic pain and play potential neuroprotection via a novel mechanism. Here, we 
demonstrated that KOR and B2R could form a heterodimer, which induced the 
Gαs/cAMP/PKA/CREB signaling pathway after treatment with Dyn A(1–13), ﬁnally resulting 
in a signiﬁcant increase in cell proliferation. 
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In summary, we provide clear evidence that the KOR and B2R can form heterodimers in 
co-transfected HEK293 cells, leading to new Gαs coupling after stimulation with Dyn 
A(1–13). Activation of the Gαs/cAMP/PKA signaling pathway causes an increase in CREB 
phosphorylation to enhance cell proliferation. Our study therefore defines the underlying 
mechanisms of neuroprotection modulated by heterodimerization and helps devise novel 
strategies to combat neurodegenerative diseases. Knockout KOR and/or B2R in SH-SY5Y 
cells are necessary for our present and further study. However, in vivo experiments are 
required to further investigate the roles of KOR/B2R heterodimers. 
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Figure Legends 
Fig. 1 Expression and co-localization of KOR and B2R in SH-SY5Y and HEK293 cells. 
RT-PCR revealed that SH-SY5Y cells, but not HEK293 cells, express KOR and B2R (A, B). 
Similar expression was noted for both receptors at the protein level by western blotting (C, D). 
Lane M: DNA ladder, Lane HEK: Untransfected HEK293 cells. (E) Confocal microscopy 
analysis of the co-localization of KOR and B2R was performed in HEK293 cells 
co-transfected with pEGFP-B2R (green) and pcDNA3.1-KOR. pcDNA3.1-KOR was 
immunostained with Alexa-Fluor 647 (red). Confocal microscopy images of KOR and B2R 
were merged to show regions of co-localization. DAPI was used to stain nuclei. 
Immunoﬂuorescence was measured with a Leica ﬂuorescence microscope. 
 
Fig. 2 Heterodimerization of KOR and B2R determined by BRET assays in living cells. 
(A) Heterodimerization of KOR and B2R was measured in the four indicated conditions by 
BRET. Twenty-four hours after transfection, the ﬂuorescence and luminescence of each 
sample were measured prior to every experiment to conﬁrm equal expression of Rluc while 
monitoring the increase in Venus expression. BRET ratios were analyzed and expressed as the 
means ± SEM of four experiments. 
$$
P<0.01 vs. KOR-Rluc+Venus group and 
KOR-Rluc+mOX2αR-Venus group; ***P<0.001 vs. Rluc+B2R-Venus group. (B) BRET 
saturation assay. HEK293 cells were transfected with a constant amount of the Rluc construct 
and increasing amounts of the Venus construct. The calculated BRET signals were plotted as a 
function of the total ﬂuorescence/luminescence ratios, and data were analyzed using linear 
and non-linear regression curve ﬁtting in GraphPad Prism (GraphPad Software, CA, USA). 
(C–D) Competition binding assay. HEK293 cells were co-transfected with a fixed amount of 
the KOR-Rluc and B2R-Venus plasmids and increasing amounts of B2R (C) or KOR (D) not 
fused to a donor or acceptor BRET probe. Data were expressed as means ± SEM of three 
experiments. 
*
P<0.05, 
**
P<0.01, 
***
P<0.001 vs. control group. 
 
Fig. 3 Assessment of dimerization of KOR and B2R using FRET assays. (A) FRET 
imaging of constitutive KOR-B2R heteromeric interactions in living cells. HEK293 cells were 
transiently transfected (co-expressed or individually expressed) with the following plasmids: 
(a) KOR-CFP, (b) B2R-Venus, (c) KOR-CFP and mOX2αR-Venus, and (d) KOR-CFP and 
B2R-Venus. Left-hand panels, CFP; center panels, Venus; right-hand panels, corrected FRET. 
(B) Calculated normalized FRET values were assessed and shown as described in the 
Materials and Methods. 
*** 
P<0.001 vs. other groups. Results are the means ± SEM of at least 
three independent experiments. (C) FRET imaging of constitutive KOR-B2R heteromeric 
interactions in living CHO cells. 
 
Fig. 4 KOR and B2R are in close proximity on the surface of HEK293 cells. (A) 
Detection of interactions between KOR and B2R in co-transfected HEK293 cells by the PLA. 
(B) Omission of one secondary antibody after incubation with anti-KOR and anti-B2R 
antibodies in co-transfected HEK293 cells. PLA signals were detected by Detection Reagents 
Red (red). Nuclei were stained with DAPI (blue). Each red dot represents the detection of a 
protein-protein interaction. All images are representative of three independent experiments. 
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PLA: PLA fluorescence signal. PLA/DAPI: merged PLA/DAPI signals. 
 
Fig. 5 Evaluation of the cAMP response in HEK293 cells using an EPAC BRET 
biosensor. (A) Schematic diagram of the presumptive molecular rearrangement of the EPAC 
protein with and without cAMP. (B) FSK decreased the BRET signal upon binding to 
CAMYEL (cAMP sensor using YFP-Epac-RLuc)), as measured by the decrease in 535/465 
nm fluorescence. 
****
P<0.001. (C–D) Measurement of BRET signals in HEK293 cells 
co-expressing the cAMP biosensor and KOR, B2R, or KOR and B2R and stimulated with 
Dyn A(1–13) (C) or BK (D). *P<0.05, ***P<0.001, NS: not significantly different. All the 
results are expressed as means ± SEM of four experiments. 
 
Fig. 6 BRET analysis of the effects of KOR/B2R heterodimerization on Gα protein 
subunit activation. HEK293 cells transiently expressing KOR, B2R, or KOR and B2R, 
together with Gαs-Rluc8, Gαi2-Rluc8, or Gαq-Rluc8 and unlabeled β1 and γ2, were prepared 
and analyzed as described in the figure. (A) Real-time analysis of the interaction between 
KOR/B2R heterodimers and Gαs using BRET in living cells. (B) Real-time analysis of the 
interaction between KOR/B2R heterodimers and Gαi2 using BRET in living cells. (C) 
Real-time analysis of the interaction between KOR/B2R heterodimers and Gαq using BRET 
in living cells. 
**
P<0.01, HEK293 cells co-expressing KOR and B2R vs. HEK293 cells 
expressing B2R only; 
##
P<0.01, HEK293 cells expressing KOR only vs. HEK293 cells 
co-expressing KOR and B2R, as determined by the Student's t-test. Results are the means ± 
SEM of at least four independent experiments.  
 
Fig. 7 Effect of KOR and B2R heterodimerization on CRE and SRE activities. 
Twenty-four hours after transfection with pCRE-luc (A) or pSRE-luc (B) together with 
pRL-TK, HEK293-KOR, HEK293-B2R, and HEK293-KOR/B2R cells were treated with Dyn 
A(1–13) (100 nM ﬁnal concentration) as indicated for 6 h prior to harvest. When indicated, 
cells were pretreated with PKC inhibitor BisII (1 μM for 2 h). The ﬁreﬂy and Renilla 
luciferase activities were assayed using the Dual-Luciferase® Reporter Assay System 
according to the manufacturer’s instructions. The ratio of the ﬁreﬂy luciferase luminescence 
signal to that of Renilla luciferase was determined. The results are expressed as the means ± 
SEM of six independent experiments performed with duplicate samples. (A) 
##
P<0.01, KOR 
group not treated with agonist vs. KOR group treated with Dyn A(1-13);
 ** 
P<0.01 vs. other 
groups. (B)
 **
P<0.01. 
 
Fig. 8 KOR/B2R dimer activity mediates CREB phosphorylation following Dyn A(1–13) 
treatment. (A) HEK293 cells expressing KOR, B2R, or KOR and B2R were treated with a 
constant concentration of Dyn A(1–13) (10-7 M) for 0, 5, 10, 15, 30, and 60 min. (B) HEK293 
cells expressing KOR, B2R, or KOR and B2R were treated with Dyn A(1–13) (10-11–10-7 M) 
for 5 min. The time-dependent and dose-dependent effects of the treatments were quantiﬁed 
(C–D). *P<0.05, **P<0.01 compared with single-transfected groups. (E–F) Human SH-SY5Y 
cells were treated with Dyn A(1–13) (10-9–10-6 M) for 5 min. *P<0.05, **P<0.01 vs. control 
group. All the data represent the means ± SEM of three measurements from three independent 
experiments. 
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Fig. 9 KOR/B2R dimer activity mediates CREB phosphorylation in a PKA-dependent 
and PLC-independent manner. (A–B) HEK293 cells stably expressing KOR, B2R, or 
KOR/B2R were treated with a constant concentration of Dyn A(1–13) (10-7 M) for 5 min. 
When indicated, cells were pretreated with PKA inhibitor H89 (10 μM for 30 min). **P<0.01 
vs. other groups. (C–D) HEK293 cells stably expressing KOR and B2R were stimulated with 
Dyn A(1–13) (10-7 M) for 5 min. When indicated, cells were pretreated with PLC inhibitor 
U73122 (10 μM for 30 min). **P<0.01 vs. control group. All the data represent the means ± 
SEM of three measurements from three independent experiments. 
 
Fig. 10 Proliferation of transfected cell lines in response to Dyn A(1–13). (A) 
Dose-dependent effects of Dyn A(1–13) on HEK293-KOR/B2R cell proliferation. 
Co-transfected cells not treated with Dyn A(1–13) were the control. (B) HEK293, 
HEK293-KOR, HEK293-B2R, and HEK293-KOR/B2R cells were cultured for 24 h in a 
96-well plate prior to treatment with 100 nM Dyn A(1–13) and starved overnight in 
serum-free media. Cell proliferation was measured. Untransfected HEK293 cells were the 
control. (C) Dose-dependent effects of Dyn A(1–13) on human SH-SY5Y cell proliferation. 
Cells not treated with Dyn A(1–13) were the control. Data points were determined from three 
independent experiments, each with quadruplicate samples. 
***
P<0.001, 
**
P<0.01. 
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Highlights 
• KOR and B2R form heterodimers that function as a novel pharmacological entity. 
• KOR/B2R heteromers mediate the Gαs/cAMP/CREB signaling pathway. 
• Dyn A(1–13) enhances proliferation of HEK293-KOR/B2R and SH-SY5Y cells. 
• We reveal the molecular mechanism underlying neuroprotection mediated by KOR/B2R 
heterodimers. 
